June 7, 2022
Daiichi Sankyo said on June 5 that its antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death by 50% versus chemotherapy in a global PIII trial enrolling patients with HER2 low breast cancer. The DESTINY-Breast04...read more